Biomarkers of exposure and response to environmental tobacco smoke in the pancrea

胰腺中环境烟草烟雾暴露和反应的生物标志物

基本信息

  • 批准号:
    8033333
  • 负责人:
  • 金额:
    $ 18.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-01-01 至 2013-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant) This proposal describes a systems biology approach to biomarker discovery and validation focused on exposure to environmental tobacco smoke (ETS) and its causal link to pancreatic ductal adenocarcinoma (PDAC). Cigarette smoke (CS) is an extremely complex mixture, including numerous tobacco-specific nitrosamines (TSNAs). The present proposal stems from significant advances the investigators have made in the quantification of tobacco-derived compounds and protein biomarkers using stable isotope methodology. CS is the major known environmental risk factor for PDAC, with recent studies implicating both mainstream tobacco smoke and ETS. PDAC is the 4th most common cause of cancer-related mortality in the US and is universally lethal. This research plan is based on four important observations: 1) TSNA metabolism varies greatly among individuals, and higher levels have been associated with lung cancer. 2) TSNAs have also been shown to cause PDAC in laboratory animals. 3) ETS, which contains TSNAs, causes pancreatic inflammation in exposed rats. 4) Pancreatic inflammation and PDAC result in specific changes in proteins secreted by pancreatic cells which we have extensively characterized. Based on these observations, the investigators have developed the following hypotheses: ETS exposes the pancreas to toxic chemicals exemplified by NNK and its metabolite NNAL. Inter-individual differences in metabolism cause serum and tissue levels of these toxic chemicals to vary widely, contributing to differences in PDAC susceptibility. Exposure of the pancreas to these toxic chemicals results in inflammation and secretion of biomarkers that can be quantified and used to asses an individual's risk for PDAC. To test these hypotheses, the following objectives/specific aims will be pursued: 1) To use an in vitro system to characterize and quantify proteomic and metabolomic biomarkers of pancreatic ETS exposure and biological response. 2) To develop panels of biomarkers using stable isotope labeling methodology in order to rigorously assess pancreatic ETS exposure and biological response. 3) To use serum and urine samples from PDAC subjects with quantified levels of ETS exposure and non-exposed controls to refine a biomarker panel of ETS exposure and biological response identified in aim 2. 4) To perform a replication study of the biomarker panel developed in aim 3 to assess the sensitivity and specificity of an individual's risk for PDAC. This proposal will elaborate on the innovative methods developed and significant findings already made by the principal investigator. A unique, interdisciplinary approach has been developed to execute the research described. By achieving these specific aims, this proposal will have a highly significant impact on the field. Furthermore, the investigators' results will shed important light on the etiological role of ETS in PDAC. Biomarkers developed will be used for identifying persons at increased risk for and with early stage PDAC. This translational approach will impact on clinical practice by offering the possibility of surgical resection, which is currently the only realistic option for improving survival from this devastating disease.
描述(由申请人提供)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kenneth H. Yu其他文献

Treatment update for metastatic pancreatic cancer
转移性胰腺癌的治疗更新
  • DOI:
    10.1016/s1548-5315(11)70729-x
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M. Hewitt;Kenneth H. Yu
  • 通讯作者:
    Kenneth H. Yu
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
胰腺癌的临床基因组图谱将 KRAS 突变剂量确定为总体生存的预后因素
  • DOI:
    10.1038/s41591-024-03362-3
  • 发表时间:
    2025-01-03
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Anna M. Varghese;Maria A. Perry;Joanne F. Chou;Subhiksha Nandakumar;Daniel Muldoon;Amanda Erakky;Amanda Zucker;Christopher Fong;Miika Mehine;Bastien Nguyen;Olca Basturk;Fiyinfolu Balogun;David P. Kelsen;A. Rose Brannon;Diana Mandelker;Efsevia Vakiani;Wungki Park;Kenneth H. Yu;Zsofia K. Stadler;Mark A. Schattner;William R. Jarnagin;Alice C. Wei;Debyani Chakravarty;Marinela Capanu;Nikolaus Schultz;Michael F. Berger;Christine A. Iacobuzio-Donahue;Chaitanya Bandlamudi;Eileen M. O’Reilly
  • 通讯作者:
    Eileen M. O’Reilly
A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.
一项针对胰腺腺癌 (PDAC) 和已知种系 (g)BRCA/PALB2 突变的患者进行的吉西他滨 (G)、顺铂 (C) /- veliparib (V) 的随机、多中心 II 期试验。
  • DOI:
    10.1200/jco.2020.38.4_suppl.639
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    45.3
  • 作者:
    E. O’Reilly;Jonathan W. Lee;M. Zalupski;M. Capanu;Jennifer Park;T. Golan;E. Tahover;M. Lowery;J. Chou;V. Sahai;R. Brenner;H. Kindler;Kenneth H. Yu;A. Zervoudakis;S. Vemuri;Z. Stadler;R. Do;N. Dhani;A. Chen;D. Kelsen
  • 通讯作者:
    D. Kelsen
EE56 Healthcare Resource Utilization and Economic Burden of Metastatic Pancreatic Cancer: A US Commercial andMedicare Claims Analysis From 2020to 2023
转移性胰腺癌的医疗资源利用和经济负担:2020 年至 2023 年美国商业和医疗保险索赔分析
  • DOI:
    10.1016/j.jval.2025.04.348
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    6.000
  • 作者:
    Kenneth H. Yu;Adaeze Q. Amaefule;Gergana Georgieva;Tomomi Kimura;Baoguo Jiang;Rupali Fuldeore
  • 通讯作者:
    Rupali Fuldeore
Diagnosis and Evaluation of Pancreatic Ductal Adenocarcinoma
胰腺导管腺癌的诊断与评估
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kenneth H. Yu;N. Ahmad
  • 通讯作者:
    N. Ahmad

Kenneth H. Yu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kenneth H. Yu', 18)}}的其他基金

Biomarkers of exposure and response to environmental tobacco smoke in the pancrea
胰腺中环境烟草烟雾暴露和反应的生物标志物
  • 批准号:
    8402832
  • 财政年份:
    2011
  • 资助金额:
    $ 18.07万
  • 项目类别:
Biomarkers of exposure and response to environmental tobacco smoke in the pancrea
胰腺中环境烟草烟雾暴露和反应的生物标志物
  • 批准号:
    8210822
  • 财政年份:
    2011
  • 资助金额:
    $ 18.07万
  • 项目类别:

相似海外基金

Advisory Committees
咨询委员会
  • 批准号:
    7353899
  • 财政年份:
    2006
  • 资助金额:
    $ 18.07万
  • 项目类别:
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
  • 批准号:
    0451289
  • 财政年份:
    2005
  • 资助金额:
    $ 18.07万
  • 项目类别:
    Standard Grant
Advisory Committees
咨询委员会
  • 批准号:
    7557224
  • 财政年份:
  • 资助金额:
    $ 18.07万
  • 项目类别:
Advisory Committees
咨询委员会
  • 批准号:
    7902286
  • 财政年份:
  • 资助金额:
    $ 18.07万
  • 项目类别:
Advisory Committees
咨询委员会
  • 批准号:
    7691385
  • 财政年份:
  • 资助金额:
    $ 18.07万
  • 项目类别:
Advisory Committees
咨询委员会
  • 批准号:
    8150373
  • 财政年份:
  • 资助金额:
    $ 18.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了